IS5117A - Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders - Google Patents

Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Info

Publication number
IS5117A
IS5117A IS5117A IS5117A IS5117A IS 5117 A IS5117 A IS 5117A IS 5117 A IS5117 A IS 5117A IS 5117 A IS5117 A IS 5117A IS 5117 A IS5117 A IS 5117A
Authority
IS
Iceland
Prior art keywords
dimethoxynapht
tetrahydropyrid
trifluoromethylphenyl
cerebral
ethane
Prior art date
Application number
IS5117A
Other languages
English (en)
Inventor
Croci Tiziano
Fournier Jacqueline
Guzzi Umberto
Palmieri Costantino
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of IS5117A publication Critical patent/IS5117A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IS5117A 1997-02-03 1999-07-15 Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders IS5117A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1997/000202 WO1998033502A1 (fr) 1997-02-03 1997-02-03 Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Publications (1)

Publication Number Publication Date
IS5117A true IS5117A (is) 1999-07-15

Family

ID=9502506

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5117A IS5117A (is) 1997-02-03 1999-07-15 Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Country Status (11)

Country Link
EP (1) EP0954311A1 (is)
JP (1) JP2001511141A (is)
AU (1) AU1607397A (is)
CA (1) CA2279326A1 (is)
CZ (1) CZ275399A3 (is)
EE (1) EE9900332A (is)
HU (1) HUP0000767A3 (is)
IL (1) IL130994A0 (is)
IS (1) IS5117A (is)
TR (1) TR199901722T2 (is)
WO (1) WO1998033502A1 (is)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6272180B1 (en) * 1997-11-21 2001-08-07 Sharp Laboratories Of America, Inc. Compression and decompression of reference frames in a video decoder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
JP2001511141A (ja) 2001-08-07
EE9900332A (et) 2000-02-15
HUP0000767A2 (hu) 2000-09-28
EP0954311A1 (fr) 1999-11-10
IL130994A0 (en) 2001-01-28
TR199901722T2 (xx) 2000-08-21
CZ275399A3 (cs) 1999-12-15
WO1998033502A1 (fr) 1998-08-06
AU1607397A (en) 1998-08-25
CA2279326A1 (fr) 1998-08-06
HUP0000767A3 (en) 2000-10-30

Similar Documents

Publication Publication Date Title
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
NO308854B1 (no) Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav
NO20004915L (no) Transdermalt terapeutisk system som inneholder en D2-agonist og som tilveiebringes for behandling av Parkinsons sykdom og en fremgangsmÕte for dets fremstilling
FI990268A (fi) Ei-peptidi-NK-antagonistin käytt¦ ihosairauksien ja kutinan hoitoon tarkoitettujen lääkkeiden valmistukseen
NO20003288D0 (no) Preparat for behandling av respiratoriske sykdommer og hudsykdommer, omfattende minst en leukotrienantagonist og minst ett antihistamin
EE200200214A (et) Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
HK1047548A1 (zh) 包含有米氮平和哲比隆的治療抑鬱症及其它機能紊亂症的合成藥物
NO306060B1 (no) Substituerte kanelsyreguanidider, deres anvendelse samt medikamenter inneholdende guanididene
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
SE9903995D0 (sv) New combination
NO994258L (no) Anvendelse av levobupivakain for behandling av ansiktsmigrene
NO302170B1 (no) Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav
IS5117A (is) Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders
NO973531L (no) Anvendelse av melatonin for behandling av pasienter som lider av medikamentavhengighet
EE200100527A (et) Osanetandi kasutamine meeleoluhäirete raviks kasulike ravimite valmistamiseks
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
NO993728D0 (no) Anvendelse av 1-[4-(3-trifluormeylfenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimetoksynaft-2yl)etan for fremstilling av medikamenter for behandling av cerebrale og nevronale forstyrrelser
NO308528B1 (no) Substituerte 1-naftoylguanidiner, deres anvendelse for fremstilling av medikamenter samt helbredende middel inneholdende forbindelsene
FI953622A0 (fi) Ifenprodiilin ja sen diastereoisomeerien käyttö lääkeaineiden valmistukseen, jotka lääkeaineet ovat käyttökelpoisia perifeeristen neuropatiatilojen ja keskushermoston degeneratiivisten sairauksien hoitoon
PT1064014E (pt) Medicamento para o impedimento ou tratamento de tumores especificos de papilomavirus
YU36499A (sh) Primena 1-/4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropirid -1-il/2-(6,7-dimetoksinaft-2-il)etana za dobijanje medikamenata za neurotrofno dejstvo